References
Karikó, K. et al. Mol. Ther. 16, 1833–1840 (2008).
Karikó, K., Muramatsu, H., Ludwig, J. & Weissman, D. Nucleic Acids Res. 39, e142 (2011).
Kormann, M.S. et al. Nat. Biotechnol. 29, 154–157 (2011).
Mays, L.E. et al. J. Clin. Invest. 123, 1216–1228 (2013).
Karikó, K., Muramatsu, H., Keller, J.M. & Weissman, D. Mol. Ther. 20, 948–953 (2012).
Melton, K.R. et al. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L543–L549 (2003).
Schultze, N., Burki, Y., Lang, Y., Certa, U. & Bluethmann, H. Nat. Biotechnol. 14, 499–503 (1996).
Nogee, L.M. Annu. Rev. Physiol. 66, 601–623 (2004).
Clark, J.C. et al. Proc. Natl. Acad. Sci. USA 92, 7794–7798 (1995).
Wang, Y. et al. Mol. Ther. 21, 358–367 (2013).
Kumar, M.N. et al. J. Nanosci. Nanotechnol. 4, 990–994 (2004).
Nafee, N., Taetz, S., Schneider, M., Schaefer, U.F. & Lehr, C.M. Nanomedicine 3, 173–183 (2007).
Urnov, F.D. et al. Nature Biotechnology 435, 646–651 (2005).
Doyon, Y. et al. Nat. Biotechnol. 26, 702–708 (2008).
Ravi Kumar, M.N., Bakowsky, U. & Lehr, C.M. Biomaterials 25, 1771–1777 (2004).
Held, H.D., Martin, C. & Uhlig, S. Br. J. Pharmacol. 126, 1191–1199 (1999).
Pfaffl, M.W., Horgan, G.W. & Dempfle, L. Nucleic Acids Res. 30, e36 (2002).
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft (DFG KO 4258/2-1, to M.S.D.K and L.E.M.), fortüne grant (no. 1980-0-0, to M.S.D.K.), by the European Respiratory Society (Maurizio Vignola Award, to M.S.D.K.), in part by the Mukoviszidose e.V. (S03/12 to M.S.D.K.), in part by the Deutsche Forschungsgemeinschaft Emmy Noether Programme (HA 5274/3-1, to D. H.), in part by the Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA Twinning Grant 22-0-0 to S.B.-H.) and in part by DFG (to B.N., S.B.-H. and M.G. (970/8.1)). Site-specific nucleases were kindly provided by Sangamo BioSciences. Thank you to D. Fraude for excellent illustration support. Primary antibody against SP-B was kindly provided by M.G.
Author information
Authors and Affiliations
Contributions
M.S.D.K. designed research, and together with A.J.M. and A.D., carried out experiments and analyzed data. B.M. performed the isolated lung experiments, and together with S.B.-H., participated in the interpretation and analysis of the data, with S.B.-H. and B.N. providing administrative and technical support. M.A., E.M., B.L., L.E.M., J.R., D.M.B., P.R., P.S., F.Z., A.S., M.C. and M.B. conceived and performed experiments. M.G., M.S., R.H., D.H. and C.-M.L. provided materials. M.S.D.K. and L.E.M. wrote the manuscript. All authors discussed results and implications, commented on or edited parts of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
M.S.D.K. and L.E.M. are listed as co-inventors on a patent application related to this work. M.S.D.K. is an inventor on a patent licensed to the biopharmaceutical company Ethris GmbH.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–22, Supplementary Sequences and Supplementary Discussion (PDF 48690 kb)
Source data
Rights and permissions
About this article
Cite this article
Mahiny, A., Dewerth, A., Mays, L. et al. In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat Biotechnol 33, 584–586 (2015). https://doi.org/10.1038/nbt.3241
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3241
- Springer Nature America, Inc.
This article is cited by
-
Emerging Treatments for Childhood Interstitial Lung Disease
Pediatric Drugs (2024)
-
A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency
Nature Communications (2020)
-
Reversal of Surfactant Protein B Deficiency in Patient Specific Human Induced Pluripotent Stem Cell Derived Lung Organoids by Gene Therapy
Scientific Reports (2019)
-
mRNA as novel technology for passive immunotherapy
Cellular and Molecular Life Sciences (2019)
-
Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors
Molecular and Cellular Pediatrics (2018)